Cited by 1,858HER2/EGFR in Cancer ResearchPI3K/AKT/mTOR signaling in cancerBreast Cancer Treatment Studies

The DOI matches its Crossref record; 65 of the 70 references it cites were found in a registry or an index.

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Open access

Nagata, Yoichi, Lan, Keng-Hsueh, Zhou, Xiaoyan, Tan, Ming, Esteva, Francisco J., Sahin, Aysegul A., Klos, Kristine S., Li, Ping, Monia, Brett P., Nguyen, Nina T., Hortobagyi, Gabriel N., Hung, Mien-Chie, Yu, Dihua·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.06.022

Open this paper in CoChat — free account Open PDF

Abstract

The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate, however, is limited and what determines trastuzumab response is poorly understood. Here we report that PTEN activation contributes to trastuzumab's antitumor activity. Trastuzumab treatment quickly increased PTEN membrane localization and phosphatase activity by reducing PTEN tyrosine phosphorylation via Src inhibition. Reducing PTEN in breast cancer cells by antisense oligonucleotides conferred trastuzumab resistance in vitro and in vivo. Patients with PTEN-deficient breast cancers had significantly poorer responses to trastuzumab-based therapy than those with normal PTEN. Thus, PTEN deficiency is a powerful predictor for trastuzumab resistance. Additionally, PI3K inhibitors rescued PTEN loss-induced trastuzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.06.022

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
PTEN , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway
Cantley, L. C., & Neel, B. G. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.8.4240 · Cited by 2,018
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,637
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers
Mutter, G. L. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.11.924 · Cited by 829
THE IMPACT OF NATIONAL CANCER ACT
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766
p185 HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor
Hudziak, R. M., Phillips, G. D. L., Winget, M., FENDLY, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165-1172.1989 · Cited by 750
Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer
Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 744
Src in cancer: deregulation and consequences for cell behaviour
Frame, M. C. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00040-9 · Cited by 696
Tumor Suppressor PTEN Mediates Sensing of Chemoattractant Gradients
Iijima, M., & Devreotes, P. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00745-6 · Cited by 677
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., SAID, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 608
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten +/− mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M. S., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 568
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
Esteva, F. J., Valero, V., Booser, D. J., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 562
Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L. K., Kaptain, S., Bach, A. M., Panageas, K. S., Arroyo, C. D., Valero, V., Currie, V. E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 546
PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G 1 cell cycle arrest in human glioblastoma cells
Li, D., & Sun, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15406 · Cited by 491
MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.
Teng, D., Hu, R. H., Lin, H., Davis, T., Iliev, D., Frye, C., Swedlund, B., Hansen, K. L., Vinson, V. L., Gumpper, K. L., et al. (1997) · PubMed · Cited by 465
Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., & Schnitt, S. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.1983 · Cited by 456
Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
Yu, D., & Hung, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203972 · Cited by 431
PTEN: The down side of PI 3-kinase signalling
Leslie, N. R., & Downes, C. P. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00234-0 · Cited by 415
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies
Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A., & Greene, M. I. (1985) · Cell · doi:10.1016/s0092-8674(85)80050-7 · Cited by 398
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
Valero, V., Holmes, F. A., Walters, R. S., Theriault, R. L., Esparza, L., Fraschini, G., Fonseca, G. A., Bellet, R. E., Buzdar, A. U., & Hortobágyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2886 · Cited by 385
Immunohistochemical Evidence of Loss of PTEN Expression in Primary Ductal Adenocarcinomas of the Breast
Perren, A. A., Weng, L., Boag, A. H., Ziebold, U., Thakore, K. S., Dahia, P. L. M., Komminoth, P., Lees, J. A., Mulligan, L. M., Mutter, G. L., et al. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65227-3 · Cited by 379
HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway
Zhou, B. P., Hu, M. C. ‐., Miller, S. A., Yu, Z., Xia, W., Lin, S., & Hung, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.8027 · Cited by 371
Efp targets 14-3-3σ for proteolysis and promotes breast tumour growth
Urano, T., Saito, T., Tsukui, T., Fujita, M., Hosoi, T., Muramatsu, M., Ouchi, Y., & Inoue, S. (2002) · Nature · doi:10.1038/nature00826 · Cited by 357
Overexpression of ErbB2 Blocks Taxol-Induced Apoptosis by Upregulation of p21Cip1, which Inhibits p34Cdc2 Kinase
Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353
The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells
Lu, Y., Lin, Y.-Z., LaPushin, R., Cuevas, B. D., Fang, X., Yu, S. X., Davies, M. A., Khan, H., Furui, T., Mao, M., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203183 · Cited by 323
The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region
Georgescu, M.-M., Kirsch, K. H., Akagi, T., Shishido, T., & Hanafusa, H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.10182 · Cited by 318
Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome
Faneyte, I. F., Schrama, J. G., Peterse, J. L., Pl, R., Rodenhuis, S., & van de Vijver, M. J. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600749 · Cited by 307
Loss of Expression of the PTEN Gene Protein Product Is Associated with Poor Outcome in Breast Cancer
Depowski, P. L., Rosenthal, S. I., & Ross, J. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880371 · Cited by 296
Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
Shepard, H. M., Phillips, G. D. L., Sarup, J. C., FENDLY, B. M., Maneval, D. C., Mordenti, J. J., Figari, I. S., Kotts, C. E., Palladino, M. A., Ullrich, A., et al. (1991) · Journal of Clinical Immunology · doi:10.1007/bf00918679 · Cited by 295
Molecular targets for breast cancer therapy and prevention
Bange, J., Zwick, E., & Ullrich, A. (2001) · Nature Medicine · doi:10.1038/87872 · Cited by 291
Interaction of the Tumor Suppressor PTEN/MMAC with a PDZ Domain of MAGI3, a Novel Membrane-associated Guanylate Kinase
Wu, Y. L., Dowbenko, D. J., Spencer, S. D., Laura, R. P., Lee, J., Gu, Q., & Lasky, L. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909741199 · Cited by 267
Mechanism of action of anti-HER2 monoclonal antibodies
Baselga, J., & Albanell, J. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_1.s35 · Cited by 266
Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades
Lu, Y., Yu, Q., Liu, J. H., Zhang, J., Wang, H., Koul, D., McMurray, J. S., Fang, X., Yung, W. K. A., Siminovitch, K. A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303621200 · Cited by 264
Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice
Butler, M., McKay, R. A., Popoff, I., Gaarde, W. A., Witchell, D. R., Murray, S. F., Dean, N. M., Bhanot, S., & Monia, B. P. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1028 · Cited by 218
Overexpression of p53 and prognosis in breast cancer
Friedrichs, K., Gluba, S., Eidtmann, H., & Jonat, W. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12 · Cited by 210
Src family kinases and HER2 interactions in human breast cancer cell growth and survival
Jablonski, A. B., Biscardi, J. S., Peavy, D. R., Tice, D. A., Romney, D. A., & Parsons, S. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204205 · Cited by 185
PI 3-Kinases and PTEN
Comer, F. I., & Parent, C. A. (2002) · Cell · doi:10.1016/s0092-8674(02)00765-1 · Cited by 132
Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis
Tan, M., Jing, T., Lan, K., Neal, C. L., Li, P., Lee, S., Fang, D., Nagata, Y., Liu, J., Arlinghaus, R. B., et al. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00510-5 · Cited by 128
Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol
Yu, D., Liu, B., Jing, T., Sun, D., Price, J. E., Singletary, S. E., Ibrahim, N., Hortobágyi, G. N., & Hung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201729 · Cited by 127
Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues
Chui, X., Egami, H., Yamashita, J., Kurizaki, T., Ohmachi, H., Yamamoto, S., & Ogawa, M. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.236 · Cited by 117
Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee, S., Yang, W., Lan, K., Sellappan, S., Klos, K. S., Hortobágyi, G. N., Hung, M., & Yu, D. (2002) · PubMed · Cited by 109
Roles of plakoglobin end domains in desmosome assembly
Palka, H. L., & Green, K. J. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.19.2359 · Cited by 109
ERBB-2 overexpression confers PI 3′ kinase-dependent invasion capacity on human mammary epithelial cells
Ignatoski, K. M. W., Maehama, T., Markwart, S. M., Dixon, J. E., Livant, D. L., & Ethier, S. P. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0979 · Cited by 95
Up-regulation of vascular endothelial growth factor in breast cancer cells by the heregulin-beta1-activated p38 signaling pathway enhances endothelial cell migration.
Xiong, S., Grijalva, R., Zhang, L., Nguyen, N. T., Pisters, P. W. T., Pollock, R. E., & Yu, D. (2001) · PubMed · Cited by 92
Unraveling Resistance to Trastuzumab (Herceptin): Insulin-Like Growth Factor-I Receptor, a New Suspect
Albanell, J., & Baselga, J. M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1830 · Cited by 88
Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Muthuswamy, S. K., & Wj, M. (1995) · PubMed · Cited by 78
Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan, M., Grijalva, R., & Yu, D. (1999) · PubMed · Cited by 61
PTEN and Cancer
Parsons, R. E., & Simpson, L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-328-3:147 · Cited by 61
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity
Koul, D., Jasser, S. A., Lu, Y., Davies, M. A., Shen, R., Shi, Y., Mills, G. B., & Yung, W. A. (2002) · Oncogene · doi:10.1038/sj.onc.1205296 · Cited by 55
Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity
Koul, D., Jasser, S. A., Lu, Y., et al. (2002) · Oncogene · doi:10.1038/sj/onc/1205296 · Cited by 51
Antibodies Stage a Comeback in Cancer Treatment
Dickman, S. (1998) · Science · doi:10.1126/science.280.5367.1196 · Cited by 46
Src Phosphorylates Grb2-associated Binder 1 upon Hepatocyte Growth Factor Stimulation
Chan, P.-C., Chen, Y., Cheng, C.-H., Yu, K.-C., Cary, L. A., Shu, K., Ho, W. L., & Chen, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305745200 · Cited by 44
Monoclonal Antibody Therapy of Human Cancer
Foon, K. A., & Morgan, A. C. (2012) · Medical Entomology and Zoology · Cited by 12
Src in cancer
Frame, M. C. (2002) · Biochimica et Biophysica Acta · Cited by 3

Flagged first, then by citations

5 of the 70 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Petit, 1997, Neutralizing antibodies against epidermal growth factor and ErbB2/neu receptor tyrosine kinase down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo, Am. J. Pathol., 151, 1523

Sorted by citations

Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., & Mills, G. B. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1902 · Cited by 2,214

See all 1,858

Authors: Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., Hortobagyi, G. N., Hung, M.-C., & Yu, D.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Ionis Pharmaceuticals (United States) (US)
Corresponding author: Yu, Dihua
ORCID: Lan, Keng-Hsueh
Zhou, Xiaoyan
Tan, Ming
Esteva, Francisco J.
Li, Ping
Monia, Brett P.
Hung, Mien-Chie
Yu, Dihua
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-08
Volume: 6
Issue: 2
Pages: 117-127
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.06.022
OpenAlex: W2059411043
Cited by: 1,858
References: 70
Citations by year: 2026: 19 · 2025: 29 · 2024: 35 · 2023: 82 · 2022: 52 · 2021: 50 · 2020: 60 · 2019: 56 · 2018: 66 · 2017: 68 · 2016: 88 · 2015: 109 · 2014: 119 · 2013: 125 · 2012: 123
FWCI: 43.34
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3272 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ca060488-09)
National Cancer Institute (P01CA099031, 2R01-CA60488, P30CA016672)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords: PTEN, trastuzumab, trastuzumab resistance, ERBB2, HER2-positive breast cancer, Src kinase inhibition, PI3K inhibitors, predictive biomarkers, antisense oligonucleotides
MeSH terms: Trastuzumab, Phosphoinositide-3 Kinase Inhibitors, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Enzyme Activation, Enzyme Inhibitors, Female, Humans, Mice, Nude, Neoplasm Transplantation, Phosphoric Monoester Hydrolases, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Oligonucleotides, Antisense, Protein Serine-Threonine Kinases, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, src-Family Kinases, Phosphatidylinositol 3-Kinases, Tumor Suppressor Proteins, Cell Line, Tumor, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks